Summary: Researchers have identified a protective brain pathway that may slow Parkinson’s disease progression by preserving dopamine-producing neurons, with this neuroprotective effect observed only in female models.
The study shows that increasing the presence of nicotine-responsive receptors on nerve cells — without exposing the brain to nicotine itself — preserved neural integrity and reduced degeneration. The protective response was robust in females but absent in males, pointing to a fundamental biological sex difference in how the brain defends against Parkinson’s disease.
Key Research Findings
- Disease-modifying potential: Unlike current treatments that primarily manage symptoms, this pathway acts by preserving dopamine-producing neurons, offering the potential to slow the underlying progression of Parkinson’s disease.
- Nicotine receptors without nicotine: The researchers increased the availability of receptors that normally respond to acetylcholine — and to which nicotine binds — using genetic techniques, avoiding exposure to addictive nicotine or nicotine-like drugs.
- Female-specific protection: The protective mechanism was clearly engaged in female models and absent in males, with females showing preserved dopamine neurons and healthier surrounding tissue.
- Neural integrity preserved: In females, reinforcing this pathway prevented activation of cell-death signaling and lowered reactive changes in neighboring glial cells, resulting in more stable neural tissue.
- Sex as a biological driver: The team highlights that sex differences in hormones, receptor trafficking and cellular regulation are central to Parkinson’s biology and must be considered when developing future therapies.
Source: Texas A&M
Summary of the study: Published in the Journal of Neuroscience, the research found that genetically increasing the presence of β2 subunit-containing neuronal nicotinic acetylcholine receptors preserved dopamine-producing neurons and reduced degeneration markers in female preclinical models of Parkinson’s disease.
Crucially, neuroprotection was achieved by boosting receptor availability and function without administering nicotine. That distinction is important because nicotine is addictive and affects many body systems, making it unsuitable for long-term therapy. The new approach aims to engage the receptor systems that nicotine targets naturally, while avoiding harmful substances.
“This work is about keeping neurons alive longer,” said Dr. Rahul Srinivasan, associate professor of neuroscience at Texas A&M University Naresh K. Vashisht College of Medicine. “If you can preserve dopamine-producing cells, you have a real opportunity to slow the rate at which the disease advances.”
Tobacco still bad for you
Researchers have long studied how nicotine affects the brain because nicotine interacts with receptor systems involved in movement and neuronal communication. However, nicotine’s addictive properties and systemic harms make it an inappropriate therapeutic agent. The present findings instead point to a way to bolster the brain’s own protective pathways — the same receptor systems nicotine happens to engage — without exposing patients to tobacco or nicotine.
The pathway at the center of this work involves receptors that normally bind the neurotransmitter acetylcholine. By using gene editing to boost expression and proper trafficking of β2-containing neuronal nicotinic acetylcholine receptors (β2* nAChRs) to relevant parts of dopamine neurons, the team strengthened a protective mechanism already present in the brain.
Parkinson’s disease progresses as dopamine-producing neurons gradually die. Current therapies can improve symptoms by replacing dopamine or mimicking its action, but they do not prevent the ongoing loss of neurons that drives worsening disability. Strengthening innate neuroprotective pathways offers a strategy aimed at altering the disease course itself.
Why only females?
A striking result of the study is that neuroprotection from receptor upregulation was restricted to female models. Across multiple independent measures — behavioral outcomes, preservation of substantia nigra dopamine neurons, suppression of pro-death endoplasmic reticulum stress signals, and reduced astrocytic reactivity — females consistently showed benefit while males did not.
Srinivasan and colleagues note that this difference is substantial, not subtle. Biological sex likely affects receptor trafficking, hormonal regulation (including the role of estrogens), and intracellular stress responses, all of which can shape how neurons respond to injury and to protective interventions. These findings reinforce that sex is a core variable in Parkinson’s research and treatment development.
Toward treatments that slow the disease itself
Because this pathway preserves the neurons that Parkinson’s disease destroys, rather than simply compensating for their loss, the results support a growing effort to develop disease-modifying therapies. Preserving functional dopamine neurons for additional years could meaningfully slow clinical progression and improve quality of life for people with Parkinson’s.
Future work will need to translate these findings into strategies that are safe and effective in people, including understanding how to target the pathway without side effects and whether human biology recapitulates the female-specific protection seen in these models. The clear takeaway is that slowing Parkinson’s may depend on helping the brain protect the cells it cannot afford to lose.
Key Questions Answered:
A: No. Nicotine is addictive and harmful. The significance of this study is that researchers can engage the brain’s protective receptor system without using nicotine itself.
A: The most likely explanations involve sex differences in hormone signaling, receptor trafficking and cellular stress responses. These biological differences influence how neurons activate protective pathways and respond to injury.
A: The researchers used genetic methods to upregulate β2-containing nicotinic acetylcholine receptors and improve their localization on dopamine neurons. Increasing receptor availability in the right neuronal compartments strengthened the cells’ resilience against degeneration.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was added by staff to clarify findings and implications.
About this Parkinson’s disease research news
Author: Lesley Henton
Source: Texas A&M
Contact: Lesley Henton – Texas A&M
Image: Image credited to Neuroscience News
Original Research: Closed access. Title: “Genetically encoded constitutive upregulation of β2 subunit containing neuronal nicotinic acetylcholine receptors is neuroprotective in female parkinsonian mice.” Authors: Gauri Pandey, Roger C. Garcia, Debanjana Das, Akilesh R. Mohan, Cristobal Rodriguez, Donovan Pollock, Nethra Karthik, Sushmitha Nalluri, Tan Nguyen, Christopher Polo, Sara M. Zarate, Mendell Rimer and Rahul Srinivasan. Journal of Neuroscience. DOI: 10.1523/JNEUROSCI.1368-25.2026
Abstract
Genetically encoded constitutive upregulation of β2 subunit containing neuronal nicotinic acetylcholine receptors is neuroprotective in female parkinsonian mice
Parkinson’s disease is expected to increase substantially by 2050, creating an urgent need for disease-modifying treatments. Prior work showed that low doses of certain nicotinic receptor partial agonists could protect dopamine neurons in female mice by reducing endoplasmic reticulum (ER) stress, and that this protection depended on 17β‑estradiol. This raised the question of whether increasing β2-containing nicotinic acetylcholine receptors (β2* nAChRs) alone — without any nicotinic ligands — could provide neuroprotection.
To test this, the team generated a novel transgenic mouse line with constitutive upregulation of β2* nAChRs. Surprisingly, only female β2-upregulated mice showed upregulation of endoplasmic reticulum-exit sites in substantia nigra dopamine neurons and demonstrated neuroprotection across four independent measures: reduced contralateral apomorphine-induced rotations, preservation of substantia nigra dopamine neurons, suppression of the proapoptotic ER stress protein C/EBP homologous protein, and reduced astrocytic reactivity.
These β2-upregulated mice provide a valuable model for studying the role of nAChR upregulation in neurological disorders including addiction, anxiety, depression and dementia, and they highlight the importance of sex as a key factor in neuroprotective strategies.